This Chinese oncology drugmaker is set for catalyst-heavy 2026 Feb 27, 2026 08:00PM
BeiGene (BGNE) Announces TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy Dec 27, 2024 06:01AM
BeiGene (BGNE) to Change Nasdaq Ticker Symbol to “ONC” Dec 23, 2024 06:25AM
TD Cowen Reiterates Buy Rating on BeiGene, Ltd. (BGNE) Dec 17, 2024 10:19AM
Morgan Stanley Assumes BeiGene, Ltd. (BGNE) at Overweight Dec 3, 2024 08:34AM


Nov 29, 2024 08:35AM BeiGene, Ltd. (BGNE) PT Raised to $207 at Bernstein SocGen Group
Nov 27, 2024 06:00AM BeiGene (BGNE) Announces EU Approval of TEVIMBRA
Nov 13, 2024 11:15AM BeiGene, Ltd. (BGNE) PT Raised to $260 at TD Cowen
Nov 12, 2024 06:01AM BeiGene (BGNE) Tops Q3 EPS by 95c
Oct 28, 2024 06:22AM BeiGene (BGNE) Announces Passing of Director Donald Glazer
Oct 22, 2024 05:59AM BeiGene, Ltd. (BGNE) PT Raised to $235 at JPMorgan
Sep 26, 2024 06:06AM BeiGene (BGNE) Appoints Shalini Sharp to its Board
Sep 18, 2024 02:12AM JMP Securities Starts BeiGene, Ltd. (BGNE) at Market Outperform
Sep 17, 2024 07:01AM BeiGene (BGNE) Receives Israeli Ministry of Health Approval for TEVIMBRA for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
Sep 9, 2024 07:02AM BeiGene (BGNE) Appoints Matt Shaulis as GM of North America
Aug 23, 2024 09:23AM BeiGene, Ltd. (BGNE) PT Lowered to $307 at Morgan Stanley
Aug 19, 2024 07:32AM TD Cowen Reiterates Buy Rating on BeiGene, Ltd. (BGNE)
Jul 23, 2024 07:00AM BeiGene (BGNE) Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility
Jul 22, 2024 12:19PM Jefferies Reiterates Buy Rating on BeiGene, Ltd. (BGNE)
Jul 18, 2024 06:30AM BeiGene (BGNE) Appoints Aaron Rosenberg as CFO